<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983940</url>
  </required_header>
  <id_info>
    <org_study_id>20200971</org_study_id>
    <nct_id>NCT04983940</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction After Switching to Oral Testosterone Undecanoate</brief_title>
  <official_title>Patient Satisfaction After Switching to Oral Testosterone Undecanoate in Men Currently on Testosterone Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clarus Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate patient satisfaction with an oral&#xD;
      testosterone agent, Jatenzo, compared to other forms of testosterone therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient satisfaction as measured by TSQM-9</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication (TSQM-9) has a total score ranging from 8 to 53 with the higher score indicating higher patient satisfaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in low testosterone symptoms as measured by qADAM questionnaire</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months</time_frame>
    <description>Quantitative Androgen Deficiency in the Aging Male (qADAM) has a total score ranges between 10 (most symptomatic) and 50 (least symptomatic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in testosterone levels</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months</time_frame>
    <description>Testosterone levels measured in ng/dL analyzed from peripheral venous puncture blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estrogen levels</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months</time_frame>
    <description>Estrogen levels measured in pg/mL analyzed from peripheral venous puncture blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hematocrit levels</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months</time_frame>
    <description>Hematocrit levels measured as a percentage analyzed from peripheral venous puncture blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSA levels</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months</time_frame>
    <description>Prostate Specific Antigen (PSA) levels measured in ng/mL analyzed from peripheral venous puncture blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting preference with the use of Jatenzo</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants responding 'yes' to a single question self-reported survey asking if the use of Jatenzo is preferred compared to prior testosterone therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Testosterone Deficiency</condition>
  <arm_group>
    <arm_group_label>Jatenzo Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive Jatenzo for 26 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jatenzo</intervention_name>
    <description>237 mg soft gel capsule taken twice a day by mouth with food.</description>
    <arm_group_label>Jatenzo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign and date the study consent form(s) which have been approved by an&#xD;
             Institutional Review Board (IRB). Written consent must be obtained prior to the&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          2. Males between 18 and 65 years of age.&#xD;
&#xD;
          3. Documented diagnosis of testosterone deficiency.&#xD;
&#xD;
          4. Prior treatment with testosterone therapy at the time of enrollment with adequate&#xD;
             control of low testosterone symptoms. Serum total testosterone &lt; 300 ng/dL on 2&#xD;
             measurements prior to the initiation of testosterone therapy. Patients must have&#xD;
             completed an adequate washout period following prior testosterone therapy (4 weeks for&#xD;
             gels and injection based therapies and 16 weeks for subcutaneous pellets).&#xD;
&#xD;
          5. Judged to be in good general health as determined by the principal investigator based&#xD;
             upon the results of a medical history, physical examination, vital signs, laboratory&#xD;
             profile and a 12-lead electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of significant sensitivity or allergy to androgens or product excipients.&#xD;
&#xD;
          2. Clinically significant findings in the pre-study examinations including abnormal&#xD;
             breast examination requiring follow-up or abnormal ECG.&#xD;
&#xD;
          3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or&#xD;
             International Prostate Symptom Score (I-PSS) score &gt; 19 points.&#xD;
&#xD;
          4. Body mass index (BMI) â‰¥ 40 kg/m2.&#xD;
&#xD;
          5. Clinically significant abnormal laboratory value, in the opinion of the investigator,&#xD;
             in serum chemistry, hematology, or urinalysis including but not limited to:&#xD;
&#xD;
               1. Baseline hemoglobin &gt; 16 g/dL&#xD;
&#xD;
               2. Hematocrit &lt; 35% or &gt; 50%&#xD;
&#xD;
          6. Poorly controlled blood pressure as defined by Systolic Blood Pressure (SBP) &gt;150 or&#xD;
             Diastolic Blood Pressure (DBP) &gt; 90 on two separate measurements&#xD;
&#xD;
          7. Concurrent use of any prohibited medications that can affect testosterone levels or&#xD;
             metabolism.&#xD;
&#xD;
          8. History of seizures or convulsions, including febrile, alcohol or drug withdrawal&#xD;
             seizures.&#xD;
&#xD;
          9. History of any clinically significant illness, infection, or surgical procedure within&#xD;
             4 weeks prior to study drug administration.&#xD;
&#xD;
         10. History of stroke or myocardial infarction within the past 5 years.&#xD;
&#xD;
         11. History of, or current or suspected, prostate or breast cancer.&#xD;
&#xD;
         12. History of, or current or suspected, pituitary abnormality.&#xD;
&#xD;
         13. History of diagnosed, severe, untreated, obstructive sleep apnea.&#xD;
&#xD;
         14. History of abuse of alcohol or any drug substance in the opinion of the investigator&#xD;
             within the previous 2 years.&#xD;
&#xD;
         15. Receipt of any investigational product within 4 weeks or within 5 half-lives prior to&#xD;
             the start of treatment.&#xD;
&#xD;
         16. Inability to understand and provide written informed consent for the study.&#xD;
&#xD;
         17. Considered by the investigator or the sponsor-designated physician, for any reason,&#xD;
             that the subject is an unsuitable candidate to receive Jatenzo&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjith Ramasamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Molina Leyba</last_name>
    <phone>305-243-4873</phone>
    <email>m.molina.leyba@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Molina Leyba</last_name>
      <phone>305-243-4873</phone>
      <email>m.molina.leyba@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjith Ramasamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ranjith Ramasamy, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

